|
| 唑来膦酸对绝经后骨质疏松症患者假体周围骨密度的影响 |
| Effects of zoledronic acid on bone mineral density around prostheses after primary total hip arthroplasty in females with postmenopausal osteoporosis |
| |
| DOI：10.3969/j.issn.1006.7108.2018.04.014 |
| 中文关键词: 唑来膦酸 骨质疏松症 骨密度 骨代谢标志物 全髋关节置换术 |
| 英文关键词:Zoledronic acid Osteoporosis Bone mineral density Bone metabolism markers Total hip arthroplasty. |
| 基金项目: |
|
| 摘要点击次数: 1020 |
| 全文下载次数: 557 |
| 中文摘要: |
| 目的 研究唑来膦酸对绝经后骨质疏松症患者假体周围骨密度的影响。 方法 选取2015年11月至2016年4月符合入组标准的32例绝经后骨质疏松症患者，随机分成对照组（16例，年龄74.4岁±5.7岁）和治疗组（16例，年龄73.3岁±6.6岁），进行为期一年的随访研究。于术后1周、3个月、6个月、12个月通过双能X线扫描（DEXA）测定假体周围骨密度值，于术前、术后3个月、6个月、12个月通过血清学检查测定相关骨代谢标志物的水平。结果 两组患者术后3个月、6个月、12个月与术后1周（基线）相比，Gruen1-7区骨密度均呈不同程度下降。术后6个月对照组在Gruen1、4、6、7区及术后12个月在Gruen1、2、4、6、7区的骨密度丢失明显高于治疗组。术后3个月、6个月、12个月对照组的骨吸收标志物(β-CTX)水平明显高于治疗组，两组的骨形成标志物（TP1NP）水平仅在术后12个月具有统计学意义（对照组高于治疗组），两组的25(OH)D水平在术后3个月、6个月、12个月均无统计学意义。 结论 绝经后骨质疏松症妇女行全髋关节置换术后使用5 mg唑来膦酸能有效预防假体周围的骨密度丢失及改善骨的重建。 |
| 英文摘要: |
| Objective To investigate the effect of zoledronic acid on periprosthetic bone mineral density (BMD) after primary total hip arthroplasty (THA) in females with postmenopausal osteoporosis. Methods From November 2015 to April 2016, 32 female patients who met the inclusion criteria were randomized into two groups: a control group and a zoledronic acid (ZOL) group. At 1 week, 3, 6 and 12 months after operation, BMD was measured using dual energy x-ray absorptiometry (DEXA). Before the operation and at 3, 6 and 12 months after the operation, serum levels of bone metabolism markers were measured. Results Loss of BMD was significantly more pronounced in the control group than in the ZOL group at zones 1, 4, 6 and 7 at 6 months and at zones 1, 2, 4, 6 and 7 at 12 months after the operation. The levels of bone-resorption marker (β-CTX) were significantly lower in the ZOL group than in the control group at 3, 6 and 12 months after operation. The changes from baseline in the levels of bone-formation marker (TP1NP) were statistically significant different only at 12 months after the operation. Conclusion Receiving an intravenous infusion of 5?mg zoledronic acid after THA can effectively reduce periprosthetic BMD loss and improve bone remodeling in females with postmenopausal osteoporosis. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |